Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COGNI-REHAB
NCT07557615Phase 1Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2027
- Primary completion
- Oct 2029
- Modality
- rProtein (Recombinant Protein), Hormone, Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant human chorionic gonadotrophin in traumatic brain injury (TBI) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: Treatment-Emergent Adverse Events at 26 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
recombinant human chorionic gonadotrophin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT07557615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557615.